Table 3.
Association of PRSS1 expression with demographic and clinical characteristics of patients with gastric carcinoma
| Group | Cases (n) | Positive rate of PRSS1 (%) |
|---|---|---|
| Sex | ||
| Male | 56 | 71.43 |
| Female | 25 | 68 |
| NGM | 34 | 13.33 |
| AH | 26 | 23.08 |
| GC | ||
| GWDAC | 5 | 60 |
| GMDAC | 17 | 64.71 |
| GPDAC | 59 | 74.58* |
| Tumor size | ||
| >3.0 cm | 49 | 65.31 |
| ≤3.0 cm | 32 | 81.25* |
| Lymph node metastasis | ||
| No | 26 | 18.18 |
| Yes | 55 | 81.82** |
| TNM staging | ||
| I-II | 32 | 56.25 |
| III-IV | 49 | 81.62** |
NGM, normal gastric mucosa; AH, atypical hyperplasia; GC, gastric carcinoma; GWDAC, well differentiated gastric adenocarcinoma; GMDAC, moderately differentiated gastric adenocarcinoma; GPDAC, poorly differentiated gastric adenocarcinoma; LMGAC, lymph node metastasis adenocarcinoma; *P<0.05, **P <0.01.